Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019.

2.

Clinical Adverse Events after Endoscopic Resection for Colorectal Lesions: A Meta-Analysis on the Antibiotic Prophylaxis.

La Regina D, Mongelli F, Fasoli A, Lollo G, Ceppi M, Saporito A, Garofalo F, Di Giuseppe M, Ferrario di Tor Vajana A.

Dig Dis. 2019 Aug 13:1-8. doi: 10.1159/000502055. [Epub ahead of print]

3.

Androgen Receptor as a Biomarker of Oral Squamous Cell Carcinoma Progression Risk.

Tomasovic-Loncaric C, Fucic A, Andabak A, Andabak M, Ceppi M, Bruzzone M, Vrdoljak D, Vucicevic-Boras V.

Anticancer Res. 2019 Aug;39(8):4285-4289. doi: 10.21873/anticanres.13593.

PMID:
31366519
4.

Environmental and behavioural head and neck cancer risk factors.

Vučičević Boras V, Fučić A, Baranović S, Blivajs I, Milenović M, Bišof V, Rakušić Z, Ceppi M, Bruzzone M.

Cent Eur J Public Health. 2019 Jun;27(2):106-109. doi: 10.21101/cejph.a5565.

PMID:
31241284
5.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
6.

Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M.

PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019.

7.

Mortality among workers exposed to asbestos at the shipyard of Genoa, Italy: a 55 years follow-up.

Merlo DF, Bruzzone M, Bruzzi P, Garrone E, Puntoni R, Maiorana L, Ceppi M.

Environ Health. 2018 Dec 29;17(1):94. doi: 10.1186/s12940-018-0439-1.

8.

No Ink on Ductal Carcinoma In Situ: A Single Centre Experience.

Fregatti P, Gipponi M, Depaoli F, Murelli F, Guenzi M, Bonzano E, Ceppi M, Friedman D.

Anticancer Res. 2019 Jan;39(1):459-466. doi: 10.21873/anticanres.13134.

PMID:
30591495
9.

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M.

Breast Cancer Res Treat. 2019 Feb;174(1):27-37. doi: 10.1007/s10549-018-5055-9. Epub 2018 Nov 21.

PMID:
30465156
10.

Use of retrieval bag in the prevention of wound infection in elective laparoscopic cholecystectomy: is it evidence-based? A meta-analysis.

La Regina D, Mongelli F, Cafarotti S, Saporito A, Ceppi M, Di Giuseppe M, Ferrario di Tor Vajana A.

BMC Surg. 2018 Nov 19;18(1):102. doi: 10.1186/s12893-018-0442-z. Review.

11.

Safety, feasibility and clinical outcome of minimally invasive inguinal hernia repair in patients with previous radical prostatectomy: A systematic review of the literature.

La Regina D, Gaffuri P, Ceppi M, Saporito A, Ferrari M, Di Giuseppe M, Mongelli F.

J Minim Access Surg. 2019 Oct-Dec;15(4):281-286. doi: 10.4103/jmas.JMAS_218_18. Review.

12.

Antibiotic administration after cholecystectomy for acute mild-moderate cholecystitis: a PRISMA-compliant meta-analysis.

La Regina D, Di Giuseppe M, Cafarotti S, Saporito A, Ceppi M, Mongelli F, Bihl F, Balzarotti Canger RC, Ferrario di Tor Vajana A.

Surg Endosc. 2019 Feb;33(2):377-383. doi: 10.1007/s00464-018-6498-0. Epub 2018 Oct 16. Review.

PMID:
30327917
13.

EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.

Kim HS, Han JY, Shin DH, Lim KY, Lee GK, Kim JY, Jacob W, Ceppi M, Weisser M, James I.

Lung Cancer. 2018 Oct;124:71-75. doi: 10.1016/j.lungcan.2018.07.026. Epub 2018 Jul 20.

PMID:
30268483
14.

Does spinal chloroprocaine pharmacokinetic profile actually translate into a clinical advantage in terms of clinical outcomes when compared to low-dose spinal bupivacaine? A systematic review and meta-analysis.

Saporito A, Ceppi M, Perren A, La Regina D, Cafarotti S, Borgeat A, Aguirre J, Van De Velde M, Teunkens A.

J Clin Anesth. 2019 Feb;52:99-104. doi: 10.1016/j.jclinane.2018.09.003. Epub 2018 Sep 18.

PMID:
30237085
15.

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M.

ESMO Open. 2018 Jun 20;3(4):e000361. doi: 10.1136/esmoopen-2018-000361. eCollection 2018.

16.

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.

Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M.

Ann Oncol. 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127.

PMID:
29873695
17.

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L.

J Clin Oncol. 2018 Jul 1;36(19):1981-1990. doi: 10.1200/JCO.2018.78.0858. Epub 2018 May 2.

PMID:
29718793
18.

DNA damage and genomic instability among workers formerly and currently exposed to asbestos.

Milić M, Neri M, Ceppi M, Bruzzone M, Munnia A, Ugolini D, Cristaudo A, Bonotti A, Peluso ME, Bonassi S.

Scand J Work Environ Health. 2018 Jul 1;44(4):423-431. doi: 10.5271/sjweh.3721. Epub 2018 Feb 19.

PMID:
29457967
19.

Epidemiology of Clostridium Difficile Infection in a Large Hospital in Northern Italy: Questioning the Ward-Based Transmission.

Piatti G, Bruzzone M, Fontana V, Mannini A, Ceppi M.

Open Microbiol J. 2017 Dec 29;11:360-371. doi: 10.2174/1874285801711010360. eCollection 2017.

20.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A.

Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19.

21.

The lymphocyte cytokinesis block micronucleus test in human populations occupationally exposed to vinyl chloride: A systematic review and meta-analysis.

Bolognesi C, Bruzzone M, Ceppi M, Kirsch-Volders M.

Mutat Res. 2017 Oct;774:1-11. doi: 10.1016/j.mrrev.2017.07.003. Epub 2017 Jul 31. Review.

PMID:
29173494
22.

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Martel S, Bruzzone M, Ceppi M, Maurer C, Ponde NF, Ferreira AR, Viglietti G, Del Mastro L, Prady C, de Azambuja E, Lambertini M.

Cancer Treat Rev. 2018 Jan;62:123-132. doi: 10.1016/j.ctrv.2017.09.009. Epub 2017 Nov 3. Review.

PMID:
29108713
23.

Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.

Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C; European Conference on Infections in Leukemia (ECIL).

J Infect. 2018 Jan;76(1):20-37. doi: 10.1016/j.jinf.2017.10.009. Epub 2017 Oct 25.

PMID:
29079323
24.

Linking the generation of DNA adducts to lung cancer.

Ceppi M, Munnia A, Cellai F, Bruzzone M, Peluso MEM.

Toxicology. 2017 Sep 1;390:160-166. doi: 10.1016/j.tox.2017.09.011. Epub 2017 Sep 18. Review.

PMID:
28928033
25.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

26.

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.

Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Review.

PMID:
28525810
27.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

28.

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.

Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L.

Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Review.

PMID:
28360014
29.

Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.

Bighin C, Dozin B, Poggio F, Ceppi M, Bruzzi P, D'Alonzo A, Levaggi A, Giraudi S, Lambertini M, Miglietta L, Vaglica M, Fontana V, Iacono G, Pronzato P, Del Mastro L.

Oncotarget. 2017 Jul 4;8(27):44800-44810. doi: 10.18632/oncotarget.14735.

30.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, Michelotti A, Bisagni G, Durando A, Valle E, Scotto T, De Censi A, Turletti A, Benasso M, Barni S, Montemurro F, Puglisi F, Levaggi A, Giraudi S, Bighin C, Bruzzi P, Del Mastro L; MIG and GIM study groups.

Eur J Cancer. 2017 Jan;71:34-42. doi: 10.1016/j.ejca.2016.10.030. Epub 2016 Dec 10.

PMID:
27951450
31.

The cytokinesis-block micronucleus (CBMN) assay in human populations exposed to styrene: A systematic review and meta-analysis.

Costa S, Ceppi M, Costa C, Silva S, Pereira C, Laffon B, Bonassi S, Teixeira JP.

Mutat Res. 2016 Oct - Dec;770(Pt A):92-105. doi: 10.1016/j.mrrev.2016.06.003. Epub 2016 Jun 23. Review.

PMID:
27894694
32.

Inter-laboratory consistency and variability in the buccal micronucleus cytome assay depends on biomarker scored and laboratory experience: results from the HUMNxl international inter-laboratory scoring exercise.

Bolognesi C, Knasmueller S, Nersesyan A, Roggieri P, Ceppi M, Bruzzone M, Blaszczyk E, Mielzynska-Svach D, Milic M, Bonassi S, Benedetti D, Da Silva J, Toledo R, Salvadori DM, Groot de Restrepo H, Filipic M, Hercog K, Aktas A, Burgaz S, Kundi M, Grummt T, Thomas P, Hor M, Escudero-Fung M, Holland N, Fenech M.

Mutagenesis. 2017 Mar 1;32(2):257-266. doi: 10.1093/mutage/gew047.

PMID:
27671865
33.

Health Issues of Primary School Students Residing in Proximity of an Oil Terminal with Environmental Exposure to Volatile Organic Compounds.

Cipolla M, Bruzzone M, Stagnaro E, Ceppi M, Izzotti A, Culotta C, Piccardo MT.

Biomed Res Int. 2016;2016:4574138. doi: 10.1155/2016/4574138. Epub 2016 Jul 3.

34.

CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.

Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, Varesano S, Boccardo S, Vigani A, Morabito A, Canessa PA, Giannoni U, Rosenberg I, Valentino A, Fedeli F, Merlo DF, Ceppi M, Riggio S, Romani M, Saverino D, Poggi A, Pistillo MP.

Cancer Immunol Immunother. 2016 Aug;65(8):909-17. doi: 10.1007/s00262-016-1844-3. Epub 2016 May 20.

PMID:
27207606
35.

Frequency of Acentric Fragments Are Associated with Cancer Risk in Subjects Exposed to Ionizing Radiation.

Fucic A, Bonassi S, Gundy S, Lazutka J, Sram R, Ceppi M, Lucas JN.

Anticancer Res. 2016 May;36(5):2451-7.

PMID:
27127157
36.

Health status of male steel workers at an electric arc furnace (EAF) in Trentino, Italy.

Cappelletti R, Ceppi M, Claudatus J, Gennaro V.

J Occup Med Toxicol. 2016 Feb 20;11:7. doi: 10.1186/s12995-016-0095-8. eCollection 2016.

37.

Clinical application of micronucleus test in exfoliated buccal cells: A systematic review and metanalysis.

Bolognesi C, Bonassi S, Knasmueller S, Fenech M, Bruzzone M, Lando C, Ceppi M.

Mutat Res Rev Mutat Res. 2015 Oct-Dec;766:20-31. doi: 10.1016/j.mrrev.2015.07.002. Epub 2015 Aug 5. Review.

PMID:
26596545
38.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

39.

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.

Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L.

Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7. Review.

PMID:
26347105
40.

Genetic determinants of quantitative traits associated with cardiovascular disease risk.

Smolková B, Bonassi S, Buociková V, Dušinská M, Horská A, Kuba D, Džupinková Z, Rašlová K, Gašparovič J, Slíž I, Ceppi M, Vohnout B, Wsólová L, Volkovová K.

Mutat Res. 2015 Aug;778:18-25. doi: 10.1016/j.mrfmmm.2015.05.005. Epub 2015 May 15.

PMID:
26043189
41.

Oxidatively damaged DNA in the nasal epithelium of workers occupationally exposed to silica dust in Tuscany region, Italy.

Peluso ME, Munnia A, Giese RW, Chellini E, Ceppi M, Capacci F.

Mutagenesis. 2015 Jul;30(4):519-25. doi: 10.1093/mutage/gev014. Epub 2015 Mar 14.

PMID:
25771384
42.

Indoor pollution and burning practices in wood stove management.

Piccardo MT, Cipolla M, Stella A, Ceppi M, Bruzzone M, Izzotti A, Valerio F.

J Air Waste Manag Assoc. 2014 Nov;64(11):1309-16.

PMID:
25509552
43.

Bisphenol-A exposures and behavioural aberrations: median and linear spline and meta-regression analyses of 12 toxicity studies in rodents.

Peluso ME, Munnia A, Ceppi M.

Toxicology. 2014 Nov 5;325:200-8. doi: 10.1016/j.tox.2014.09.008. Epub 2014 Sep 19.

PMID:
25242006
44.

Familiarity of physicians, translational researchers, nurses, and other health professionals with evidence-based medicine terms and resources.

Ugolini D, Casanova G, Ceppi M, Mattei F, Neri M.

J Cancer Educ. 2014 Sep;29(3):514-21. doi: 10.1007/s13187-014-0631-0.

PMID:
24585401
45.

Multiple recent horizontal transfers of a large genomic region in cheese making fungi.

Cheeseman K, Ropars J, Renault P, Dupont J, Gouzy J, Branca A, Abraham AL, Ceppi M, Conseiller E, Debuchy R, Malagnac F, Goarin A, Silar P, Lacoste S, Sallet E, Bensimon A, Giraud T, Brygoo Y.

Nat Commun. 2014;5:2876. doi: 10.1038/ncomms3876.

46.

Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.

Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P.

Cancer Treat Rev. 2014 Jun;40(5):675-83. doi: 10.1016/j.ctrv.2013.12.001. Epub 2013 Dec 8. Review.

PMID:
24360817
47.

Micronuclei in cord blood lymphocytes and associations with biomarkers of exposure to carcinogens and hormonally active factors, gene polymorphisms, and gene expression: the NewGeneris cohort.

Merlo DF, Agramunt S, Anna L, Besselink H, Botsivali M, Brady NJ, Ceppi M, Chatzi L, Chen B, Decordier I, Farmer PB, Fleming S, Fontana V, Försti A, Fthenou E, Gallo F, Georgiadis P, Gmuender H, Godschalk RW, Granum B, Hardie LJ, Hemminki K, Hochstenbach K, Knudsen LE, Kogevinas M, Kovács K, Kyrtopoulos SA, Løvik M, Nielsen JK, Nygaard UC, Pedersen M, Rydberg P, Schoket B, Segerbäck D, Singh R, Sunyer J, Törnqvist M, van Loveren H, van Schooten FJ, Vande Loock K, von Stedingk H, Wright J, Kleinjans JC, Kirsch-Volders M, van Delft JH; NewGeneris Consortium.

Environ Health Perspect. 2014 Feb;122(2):193-200. doi: 10.1289/ehp.1206324. Epub 2013 Nov 19.

48.

Aberrant methylation of hypermethylated-in-cancer-1 and exocyclic DNA adducts in tobacco smokers.

Peluso ME, Munnia A, Bollati V, Srivatanakul P, Jedpiyawongse A, Sangrajrang S, Ceppi M, Giese RW, Boffetta P, Baccarelli AA.

Toxicol Sci. 2014 Jan;137(1):47-54. doi: 10.1093/toxsci/kft241. Epub 2013 Oct 23.

49.

Direct visualization of the highly polymorphic RNU2 locus in proximity to the BRCA1 gene.

Tessereau C, Buisson M, Monnet N, Imbert M, Barjhoux L, Schluth-Bolard C, Sanlaville D, Conseiller E, Ceppi M, Sinilnikova OM, Mazoyer S.

PLoS One. 2013 Oct 11;8(10):e76054. doi: 10.1371/journal.pone.0076054. eCollection 2013.

50.

Estimating the lowest detectable dose of ionizing radiation by the cytokinesis-block micronucleus assay.

Tucker JD, Vadapalli M, Joiner MC, Ceppi M, Fenech M, Bonassi S.

Radiat Res. 2013 Sep;180(3):284-91. doi: 10.1667/RR3346.1. Epub 2013 Aug 9.

PMID:
23931722

Supplemental Content

Support Center